Moderna announces phase 2 data on mrna-4157 (v940), an investigational individualized neoantigen therapy, to be presented at the 2023 asco annual meeting

Asco presentations on saturday, june 3 at 4:30pm cdt and monday, june 5 at 3:00pm cdt moderna to host investor event via webcast on monday, june 5 at 6pm cdt cambridge, ma / accesswire / may 30, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that two abstracts on mrna-4157 (v940), an investigational mrna individualized neoantigen therapy, have been accepted for presentation at the 2023 american society of clinical oncology (asco) annual meeting being held june 2-6 in chicago, il. mrna-4157 (v940) is being jointly developed by moderna and merck, known as msd outside of the united states and canada.
MRNA Ratings Summary
MRNA Quant Ranking